smartcybers786@gmail.com 
A monitor shows a three-dimensional image of a human heart at the Klaus-Tschira-Institute for Integrative Computational Cardiology, department of the Heidelberg University Hospital (Universitaetsklinikum Heidelberg), in Heidelberg, Germany, August 14, 2018. — Reuters
#heart #attack #pills #equally #effective
Two major trials have shown that despite modern treatment, a decades -old pill is helpful for heart attack patients.
Yet it is not clear whether all the patients, or just some, take advantage of the so -called beta blocker medicines, which are usually suggested to everyone after a heart attack.
Two rapidly contradictory reports were presented at a major cardiology meeting in Madrid on Saturday and was published in the New England Journal of Medicine.
“It is not uncommon for trials to yield different results for trials,” said Dr. Borja Iii of Centro Nisunal De Investment Carlos Carlos III in Madrid.
“To some extent, the unusual thing is to see two trials with different results presented on the same day.”
The most important thing is that the two teams agree, which is why beta blockers reduce heart attacks, heart failure, or shared risk of death in patients without heart failure but are suffering from heart failure.
The question is whether the tablets are generally beneficial or useless for working -hearted, which is about 80 % of patients after the first heart attack.
Beta -blocker manufacturers include mamilan, nephews, tools New Tab, Fazer, Opens New Tab, Abbott, Tiv Pharmaceutical Industries, Tools New Tab, Emanuel Pharmaceuticals, Opens New Tab, Sun Pharmaceutical Industries, Opens New Tab, Open News, Open News, Tools, Open News, Open News, Open News, Open News, Open News, Open News, Open News
Drug hormones work by preventing epinentphrine and norpinephrine, thus lowering heart rate and blood pressure, reducing the workload on the heart and reducing its oxygen demand.
Both new trials included people who were suffering from a heart attack, whose hearts were still making a contract, meaning, the left ventricle was extracting at least 40 % of blood with each beating. Patients were followed for about 3.5 3.5 years in both trials.
In 5,574 volunteers at the Betamy -Dan Block Study from Norway and Denmark, the drug showed clear advantage. Investigators found that a 15 % low risk of death for patients collected to receive beta blockers or major negative cardiovascular event, especially in a heart attack, compared to non -taking patients.
According to a separate report, but among the 8,438 participants in the reboot trial in Italy and Spain, the beta blockers did not have any effect on death incidents, heart attack, or entering the hospital for heart failure.
Some differences may be due to the fact that patients did not get the same beta blockers, and scandinavine patients may have a higher risk of adverse events because they were slightly larger than Spanish and Italy patients, and most of them suffered a mild heartbreak, which was reported by Oslo.
Researchers reported in the European Heart Journal, among female participants in the reboot, with beta blockers-especially good-hearted people who receive high food-have more negative consequences than women who do not take drugs.
In the reboot, researchers see a new heart attack, heart failure, or low death rate with the use of beta blockers by lightning patients, as indicated between 40 % and 49 % through the left ventricular “Education Fractory”.
According to a report published in Lancet, the effect of all this group has been confirmed in the analysis of the Reboot, Betamy – Dan Block, and Japanese trial data.
This message for the cardiologist, Ibnis, said, “We can now confidently state that beta blockers are beneficial.
Author said that a particularly visible analysis on the use of a beta blocker by ordinary heart -function patients will be presented at the US Cardiology meeting in November.
